Literature DB >> 24387507

Dosimetric evaluation of the interplay effect in respiratory-gated RapidArc radiation therapy.

Craig Riley1, Yong Yang2, Tianfang Li2, Yongqian Zhang2, Dwight E Heron2, M Saiful Huq2.   

Abstract

PURPOSE: Volumetric modulated arc therapy (VMAT) with gating capability has had increasing adoption in many clinics in the United States. In this new technique, dose rate, gantry rotation speed, and the leaf motion speed of multileaf collimators (MLCs) are modulated dynamically during gated beam delivery to achieve highly conformal dose coverage of the target and normal tissue sparing. Compared with the traditional gated intensity-modulated radiation therapy technique, this complicated beam delivery technique may result in larger dose errors due to the intrafraction tumor motion. The purpose of this work is to evaluate the dosimetric influence of the interplay effect for the respiration-gated VMAT technique (RapidArc, Varian Medical Systems, Palo Alto, CA). Our work consisted of two parts: (1) Investigate the interplay effect for different target residual errors during gated RapidArc delivery using a one-dimensional moving phantom capable of producing stable sinusoidal movement; (2) Evaluate the dosimetric influence in ten clinical patients' treatment plans using a moving phantom driven with a patient-specific respiratory curve.
METHODS: For the first part of this study, four plans were created with a spherical target for varying residual motion of 0.25, 0.5, 0.75, and 1.0 cm. Appropriate gating windows were applied for each. The dosimetric effect was evaluated using EDR2 film by comparing the gated delivery with static delivery. For the second part of the project, ten gated lung stereotactic body radiotherapy cases were selected and reoptimized to be delivered by the gated RapidArc technique. These plans were delivered to a phantom, and again the gated treatments were compared to static deliveries by the same methods.
RESULTS: For regular sinusoidal motion, the dose delivered to the target was not substantially affected by the gating windows when evaluated with the gamma statistics, suggesting the interplay effect has a small role in respiratory-gated RapidArc therapy. Varied results were seen when gated therapy was performed on the patient plans that could only be attributed to differences in patient respiratory patterns. Patients whose plans had the largest percentage of pixels failing the gamma statistics exhibited irregular breathing patterns including substantial interpatient variation in depth of respiration.
CONCLUSIONS: The interplay effect has a limited impact on gated RapidArc therapy when evaluated with a linear phantom. Variations in patient breathing patterns, however, are of much greater clinical significance. Caution must be taken when evaluating patients' respiratory efforts for gated arc therapy.

Entities:  

Mesh:

Year:  2014        PMID: 24387507     DOI: 10.1118/1.4855956

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  15 in total

1.  Under-reported dosimetry errors due to interplay effects during VMAT dose delivery in extreme hypofractionated stereotactic radiotherapy.

Authors:  Tobias Gauer; Thilo Sothmann; Oliver Blanck; Cordula Petersen; René Werner
Journal:  Strahlenther Onkol       Date:  2018-02-15       Impact factor: 3.621

2.  Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients.

Authors:  Anna Simeonova-Chergou; Anika Jahnke; Kerstin Siebenlist; Florian Stieler; Sabine Mai; Judit Boda-Heggemann; Frederik Wenz; Frank Lohr; Lennart Jahnke
Journal:  Strahlenther Onkol       Date:  2016-01-15       Impact factor: 3.621

3.  Quantitative analysis of the intra-beam respiratory motion with baseline drift for respiratory-gating lung stereotactic body radiation therapy.

Authors:  Kenji Yasue; Hiraku Fuse; Satoshi Oyama; Koichi Hanada; Kazuya Shinoda; Hideaki Ikoma; Tatsuya Fujisaki; Yoshio Tamaki
Journal:  J Radiat Res       Date:  2022-01-20       Impact factor: 2.724

4.  Effect of plan complexity on the dosimetry, delivery accuracy, and interplay effect in lung VMAT SBRT with 6 MV FFF beam.

Authors:  Chao Ge; Huidong Wang; Kunzhi Chen; Wuji Sun; Huicheng Li; Yinghua Shi
Journal:  Strahlenther Onkol       Date:  2022-04-29       Impact factor: 4.033

Review 5.  The Practicality of ICRU and Considerations for Future ICRU Definitions.

Authors:  Annemarie Shepherd; Sara St James; Ramesh Rengan
Journal:  Semin Radiat Oncol       Date:  2018-06       Impact factor: 5.934

Review 6.  Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy.

Authors:  Nikhil Yegya-Raman; Wei Zou; Ke Nie; Jyoti Malhotra; Salma K Jabbour
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

7.  Evaluation of the target dose coverage of stereotactic body radiotherapy for lung cancer using helical tomotherapy: A dynamic phantom study.

Authors:  Masahide Saito; Hidekazu Suzuki; Naoki Sano; Kazunari Ashizawa; Kazuya Yoshizawa; Yuki Shibata; Koji Ueda; Takafumi Komiyama; Kan Marino; Shinichi Aoki; Ryo Saito; Yoshiyasu Maehata; Hiroshi Onishi
Journal:  Rep Pract Oncol Radiother       Date:  2020-01-14

8.  Evaluation of Dose Distribution in Intensity Modulated Radiosurgery for Lung Cancer under Condition of Respiratory Motion.

Authors:  Mee Sun Yoon; Jae-Uk Jeong; Taek-Keun Nam; Sung-Ja Ahn; Woong-Ki Chung; Ju-Young Song
Journal:  PLoS One       Date:  2016-09-20       Impact factor: 3.240

9.  4D dose simulation in volumetric arc therapy: Accuracy and affecting parameters.

Authors:  Thilo Sothmann; Tobias Gauer; René Werner
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

10.  Amplitude gating for a coached breathing approach in respiratory gated 10 MV flattening filter-free VMAT delivery.

Authors:  Francis Viel; Richard Lee; Ermias Gete; Cheryl Duzenli
Journal:  J Appl Clin Med Phys       Date:  2015-07-08       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.